Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 6/20 | 0.40 |
| ▸ | CTSS | P25774 | 5/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8362351 | 0.83 | MEN1 (0.41) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL556588 | 0.81 | MEN1 (0.46) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL12274268 | 0.81 | CA1 (0.51) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL1457816 | 0.81 | MEN1 (0.46) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL9600202 | 0.81 | MEN1 (0.46) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL17571386 | 0.81 | SYK (0.52) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL10475827 | 0.79 | MEN1 (0.49) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL10475828 | 0.79 | MEN1 (0.49) | MEN1GAAKMT2ATDP1SYK | |
| SCHEMBL1105702 | 0.79 | PCSK9 (0.50) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL6563149 | 0.79 | MEN1 (0.50) | MEN1GAAKMT2ATDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3442966-B1 | NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]- AND N-[(PYRIDINYLAMINO)PROPANYL]ARYLCARBOXAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2020-10-14 | — | — | EP | disclosed |
| US-10710984-B2 | N-[(Pyrimidinylamino)propanyl]-and N-[(Pyridinylamino)-propanyl]arylcarboxamides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-07-14 | — | — | US | disclosed |
| EP-3442964-B1 | NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N [(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2020-05-06 | — | — | EP | disclosed |
| US-20190112297-A1 | Novel N-[(Pyrimidinylamino)Propanyl]-and N-[(Pyridinylamino)Propanyl]Arylcarboxamides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-04-18 | — | — | US | disclosed |
| US-9884854-B2 | N-[(pyrimidinylamino)propanyl]-and N[(pyrazinylamino)proppanyl]arylcarboxamides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| WO-2017178341-A1 | NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N [(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-10-19 | — | — | WO | disclosed |
| US-20170298053-A1 | NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N [(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GHBH (DE) | 2017-10-19 | — | — | US | disclosed |
| WO-2017178343-A1 | NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N-[(PYRIDINYLAMINO)PROPANYL]ARYLCARBOXAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112297-A1 | Novel N-[(Pyrimidinylamino)Propanyl]-and N-[(Pyridinylamino)Propanyl]Arylcarboxamides | HCRTR1, HCRTR2, CNR1 | MEN1 1770/4885GAA 3415/4885KMT2A 1349/4885 |
| US-10710984-B2 | N-[(Pyrimidinylamino)propanyl]-and N-[(Pyridinylamino)-propanyl]arylcarboxamides | HCRTR1, HCRTR2, CNR1 | MEN1 1805/4885GAA 3172/4885KMT2A 1362/4885 |
| US-20170298053-A1 | NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N [(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES | HCRTR2, HCRTR1, CNR1 | MEN1 2274/4885GAA 3610/4885KMT2A 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.